| Project/Area Number |
22790137
|
|---|
| Research Category |
Grant-in-Aid for Young Scientists (B)
|
| Allocation Type | Single-year Grants |
|---|
| Research Field |
Environmental pharmacy
|
|---|
| Research Institution | Tokushima Bunri University |
|---|
Principal Investigator |
SUMI Daigo 徳島文理大学, 薬学部, 准教授 (30400683)
|
|---|
| Project Period (FY) |
2010 – 2011
|
| Project Status |
Completed (Fiscal Year 2011)
|
| Budget Amount *help |
¥4,030,000 (Direct Cost: ¥3,100,000、Indirect Cost: ¥930,000)
Fiscal Year 2011: ¥1,560,000 (Direct Cost: ¥1,200,000、Indirect Cost: ¥360,000)
Fiscal Year 2010: ¥2,470,000 (Direct Cost: ¥1,900,000、Indirect Cost: ¥570,000)
|
|---|
| Keywords | 中毒学 / 白血病 / 亜ヒ酸製剤 / 細胞分化 / レチノイン酸 / 転写因子 / ヒ素化合物 / 水チャネル / 細胞内取込 |
|---|
| Research Abstract |
In this study, we performed basic experiments to determine whether the treatment with all-trans retinoic acid(ATRA) plus arsenic trioxide(ATO) in combination is beneficial in Acute Promyelocytic Leukemia(APL) therapy than that with a single agent. In order to determine the ATRA-induced differentiation is augmented by the addition of ATO, we compared the surface expression of CD 11 b in human leukemia HL60 cells incubated with ATRA, ATO, or ATRA plus ATO. The result indicates that HL60 cells treated with ATO plus ATRA show further differentiation than those treated with ATRA alone, suggesting that cotreatment of ATO plus ATRA is more effective than the treatment with a single agent in enhancing the differentiation of HL60 cells.
|
